Ohcanbohtosat - Athena Philis‐Tsimikas
- Čájehuvvo 1 - 20 / 30
- Sirdás čuovvovaš siidui
-
1
-
2
-
3
-
4
-
5
LDL Isolated From Greek Subjects on a Typical Diet or From American Subjects on an Oleate-Supplemented Diet Induces Less Monocyte Chemotaxis and Adhesion When Exposed to Oxidative... Dahkki Sotirios Tsimikas, Athena Philis‐Tsimikas, Sophoclis P. Alexopoulos, Farhad Sigari, Christian Lee, Peter D. Reaven
Almmustuhtton 1999Artigo -
6
Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to O... Dahkki Harpreet S. Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis‐Tsimikas, Tadej Battelino
Almmustuhtton 2024Artigo -
7
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes Dahkki Bernard Zinman, Athena Philis‐Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W. Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu
Almmustuhtton 2012Artigo -
8
-
9
Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial Dahkki Helena W. Rodbard, Bertrand Cariou, Bernard Zinman, Yehuda Handelsman, Athena Philis‐Tsimikas, Trine Vang Skjøth, Ashma Rana, Chantal Mathieu
Almmustuhtton 2013Artigo -
10
-
11
Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting Dahkki Addie L. Fortmann, Samantha R. Spierling Bagsic, Laura Talavera, Isabel Maria Garcia, Haley Sandoval, Amiry Hottinger, Athena Philis‐Tsimikas
Almmustuhtton 2020Carta -
12
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>) Dahkki Chantal Mathieu, Helena W. Rodbard, Bertrand Cariou, Yehuda Handelsman, Athena Philis‐Tsimikas, Ann Marie Ocampo Francisco, Ashma Rana, Bernard Zinman
Almmustuhtton 2014Artigo -
13
Dulce Wireless Tijuana: A Randomized Control Trial Evaluating the Impact of Project Dulce and Short-Term Mobile Technology on Glycemic Control in a Family Medicine Clinic in Northe... Dahkki María Cecilia Anzaldo-Campos, Sonia Contreras Contreras, Adriana Carolina Vargas-Ojeda, Rufino Menchaca-Díaz, Addie L. Fortmann, Athena Philis‐Tsimikas
Almmustuhtton 2016Artigo -
14
Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial Dahkki Chantal Mathieu, Bruce W. Bode, Edward Franek, Athena Philis‐Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell‐Jones
Almmustuhtton 2018Artigo -
15
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people... Dahkki Athena Philis‐Tsimikas, Liana K. Billings, Robert S. Busch, Cristóbal Morales, Rakesh Sahay, Natalie Halladin, S Eggert, Kamilla Begtrup, Stewart B. Harris
Almmustuhtton 2019Artigo -
16
Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes Dahkki Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell‐Jones, Julio Rosenstock
Almmustuhtton 2022Artigo -
17
Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme Dahkki Richard M. Bergenstal, Athena Philis‐Tsimikas, Carol Wysham, Molly C. Carr, Juliana Bue‐Valleskey, Fady T. Botros, Thomas Blevins, Julio Rosenstock
Almmustuhtton 2024Artigo -
18
-
19
Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial Dahkki Athena Philis‐Tsimikas, David C. Klonoff, Kamlesh Khunti, Harpreet S. Bajaj, Lawrence A. Leiter, M. Hansen, Lone Troelsen, Steen Ladelund, Simon Heller, Thomas R. Pieber
Almmustuhtton 2020Artigo -
20
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized,... Dahkki David Russell‐Jones, Bruce W. Bode, Christophe De Block, Edward Franek, Simon Heller, Chantal Mathieu, Athena Philis‐Tsimikas, Ludger Rose, Vincent Woo, Anne Birk Østerskov, Tina Graungaard, Richard M. Bergenstal
Almmustuhtton 2017Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Internal medicine
Medicine
Endocrinology
Diabetes mellitus
Type 2 diabetes
Randomized controlled trial
Insulin
Type 1 diabetes
Glycemic
Insulin glargine
Continuous glucose monitoring
Hypoglycemia
Insulin degludec
Environmental health
Gerontology
Basal (medicine)
Clinical endpoint
Economics
Pathology
Population
Alternative medicine
Basal insulin
Chemistry
Clinical trial
Family medicine
Gastroenterology
Insulin aspart
Intensive care medicine
Physical therapy
Surgery